Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

Slides:

Advertisements

Similar presentations

WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.

Advertisements

Upfront Combination Therapy vs Step-Up Approach for PAH:

Randomisation before planned PCI with DES (n=2500)

European and US Guidelines

Preventing Thrombotic Complications in ACS: State of the Art

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

Class I Medical Therapies for CAD and PAD

Anticoagulants in Interventional Cardiology:

Glenn N. Levine et al. JACC 2016;68:

Cardiac Troponin.

Achieving Long-Term Protection Post-MI

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Access to NOAC Therapy:

Emerging Data on ACS Management From ACC

Applying New Data in Practice:

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Glenn N. Levine et al. JACC 2016;68:

Unmet Needs in the Secondary Prevention in ACS

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Optimizing Outcomes in the Management of GIST

It’s Elementary.

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

Strategies to Improve Adherence and Persistence in the Treatment of Hypertension.

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Heart Failure Management Coordinated Care Approaches

Antiplatelet Therapy and Secondary Prevention

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

Heart Failure Prevention: Mission Impossible?

Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?

Terms of Use. Terms of Use.

Anticoagulation Therapy in Patients Post-TAVR

Treatment Options to Consider

CV Risk Doesn't End in the Cath Lab

AF and PCI in Practice.

Access to NOAC Therapy:

Learning Objectives Classification of VTE Goals of VTE Treatment.

From Start to Finish: Initial and Ongoing Care for Men Receiving PrEP

Five Things You Need to Know About Secondary Prevention Post-ACS

Aspirin in Cardioprevention:

Practical Considerations to Extend Treatment for VTE

2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease Glenn N. Levine, MD, FACC, FAHA,

Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

Diabetes and Cardiovascular Disease Risk: The Hard Truth

The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.

CV Risk Doesn't End in the Cath Lab

Diabetes and Cardiovascular Disease Risk: The Hard Truth

Goals. Weight Management Goals and Approaches in Patients With Type 2 Diabetes.

Aspirin and Cardioprevention in 2018

Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

When to Start and What to Use

Duration of Dual Antiplatelet Therapy

CAD/PAD in Primary Care

Insulin in Diabetes Management: Effective Patient Selection Is Key

How to Optimize Cholesterol Management in High-Risk CV Patients

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Improving Adherence to Antiplatelet Therapy After an ACS Event

The Patient With Early Stage MF-CTCL

Nurse Practitioners: At the Forefront of HPV-Related Disease Prevention.

Patient Stories in PAH: Sequential Therapy in a FC II Patient

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

The Nurse View: Spotlight on EGFR-Mutated NSCLC

ESC Guideline on the Management of STEMI Recommendation for DAPT

Figure 3. Trials and possible strategies for un-guided and guided DAPT de-escalation. The figure shows studies and strategies on DAPT de-escalation approaches.

Many post-MI patients are not receiving optimal therapy

Antithrombotic Therapy in AF Patients Undergoing PCI

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Translating Data From Trial to Practice

Presentation transcript:

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

Panelists

Program Goals

Case Study 58-Year-Old Man Presents for 4-wk Follow Up Visit Post STEMI/Primary PCI

Case Study (cont) History of Acute Event

Hospital Course

Discharge Instructions

Aspirin Dose

Choice of P2 Y12

Routine Secondary Prevention Recommendations

β blocker Recommendations Post-STEMI in US vs Europe

Post Discharge Follow up

Post Hospital Follow up

Initial Therapy for Type 2 Diabetes

4 Week Follow Up With Cardiology

Suboptimal Adherence: A Complex and Persistent Issue

Proactive Patient Education

Case Study Patient Returns 3 mo Later

Interrupting DAPT for Elective Procedure

Optimal Duration of DAPT?

Calculation of a DAPT Score

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)